Evidence
Psychopharmacol Bull. 2024 Jul 8;54(3):97-99.
ABSTRACT
NTX is FDA-approved for opiate and alcohol use disorders as anti-craving agent. It has been used successfully off-label in other psychiatric indications. Here, we shed some light on these while examining the extant evidence.
PMID:38993658 | PMC:PMC11235578
Estimated reading time: 1 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Therapeutic Potential of Naltrexone in the Niche of Psychopharmacology
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Evidence Blueprint
Therapeutic Potential of Naltrexone in the Niche of Psychopharmacology
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Therapeutic Potential of Naltrexone in the Niche of Psychopharmacology
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
